Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study

PURPOSE: Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res Treat
Main Authors: Hur, Joon Young, Kim, Youjin, Kwon, Ghee-Young, Kang, Minyong, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Lee, Su Jin, Park, Se Hoon
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Cancer Association 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790849/
https://ncbi.nlm.nih.gov/pubmed/30653744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.604
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados